Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XGN
stocks logo

XGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
17.51M
+28.21%
-0.179
-10.72%
18.00M
+16.14%
-0.160
-20%
19.54M
+13.61%
-0.121
-42.18%
Estimates Revision
The market is revising Downward the revenue expectations for Exagen Inc. (XGN) for FY2025, with the revenue forecasts being adjusted by -0.09% over the past three months. During the same period, the stock price has changed by -22.54%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+29%
In Past 3 Month
Stock Price
Go Down
down Image
-22.54%
In Past 3 Month
Wall Street analysts forecast XGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XGN is 16.20 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast XGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XGN is 16.20 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.490
sliders
Low
15.00
Averages
16.20
High
18.00
Current: 7.490
sliders
Low
15.00
Averages
16.20
High
18.00
BTIG
Buy
maintain
$13 -> $15
2025-11-10
Reason
BTIG
Price Target
$13 -> $15
2025-11-10
maintain
Buy
Reason
BTIG raised the firm's price target on Exagen to $15 from $13 and keeps a Buy rating on the shares after its Q1 results. The company is driving a solid balance of volume and pricing gains, and is nearing positive adjusted EBITDA, the analyst tells investors in a research note.
B. Riley
Buy
upgrade
$15 -> $18
2025-11-05
Reason
B. Riley
Price Target
$15 -> $18
2025-11-05
upgrade
Buy
Reason
B. Riley raised the firm's price target on Exagen to $18 from $15 and keeps a Buy rating on the shares. The firm views the company's Q3 results as mixed but expects continued volume growth.
Canaccord
Buy
maintain
$11 -> $15
2025-10-27
Reason
Canaccord
Price Target
$11 -> $15
2025-10-27
maintain
Buy
Reason
Canaccord raised the firm's price target on Exagen to $15 from $11 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results noting that the life science tools secot remains challenged amid multiple headwinds including tariffs, funding uncertainty, and China issues.
KeyBanc
Overweight
maintain
$12 -> $15
2025-10-14
Reason
KeyBanc
Price Target
$12 -> $15
2025-10-14
maintain
Overweight
Reason
KeyBanc raised the firm's price target on Exagen to $15 from $12 and keeps an Overweight rating on the shares. The firm is raising its FY25 and FY26 estimates, as KeyBanc believes visibility on revenue is increasing. Exagen's management team increased test reimbursement 27% in 2024 to $398 with increased sales discipline and recent administrative law judge wins also boosting commercial diagnostic reimbursement. With a $650 long-term pricing goal, KeyBanc views Exagen as well positioned to exceed consensus.
B. Riley
Anderson Schock
initiated
$15
2025-09-11
Reason
B. Riley
Anderson Schock
Price Target
$15
2025-09-11
initiated
Reason
B. Riley analyst Anderson Schock initiated coverage of Exagen with a Buy rating and $15 price target, reflecting 50% potential upside. Exagen is a diagnostics company that develops blood tests to help rheumatologists diagnose autoimmune diseases, the analyst tells investors in a research note. The firm believes the company's AVISE CTD is well positioned to become the "gold standard" for both lupus and rheumatoid arthritis diagnosis.
KeyBanc
Sector Weight -> Overweight
upgrade
$12
2025-07-30
Reason
KeyBanc
Price Target
$12
2025-07-30
upgrade
Sector Weight -> Overweight
Reason
KeyBanc last night upgraded Exagen to Overweight from Sector Weight with a $12 price target. The firm sees higher revenue visibility due to the company's improved pricing, salesforce additions, and new payers like Tricare. Exagen is a leader in autoimmune diagnostics and its revenue guidance implies growth of 17%-25% in 2025, the analyst tells investors in a research note. KeyBanc believes the company is working to expand its leading market position in novel connective tissue diagnosis with new biomarkers in early 2026 to increase the "moat" around its core test.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Exagen Inc (XGN.O) is -13.04, compared to its 5-year average forward P/E of -5.34. For a more detailed relative valuation and DCF analysis to assess Exagen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.34
Current PE
-13.04
Overvalued PE
-0.17
Undervalued PE
-10.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-13.56
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
15.13
Undervalued EV/EBITDA
-42.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.06
Current PS
0.00
Overvalued PS
3.58
Undervalued PS
0.55
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XGN News & Events

Events Timeline

(ET)
2025-11-04
08:09:16
Exagen reaffirms FY25 revenue forecast of $65M-$70M, with consensus at $67.48M.
select
2025-11-04
08:07:55
Exagen announces Q3 earnings per share of 31 cents, surpassing consensus estimate of 16 cents.
select
2025-07-29 (ET)
2025-07-29
08:02:35
Exagen sees FY25 revenue $65M-$70M, consensus $65.87M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-10Benzinga
BTIG Reaffirms Buy Rating on Exagen, Increases Price Target to $15

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve trading outcomes.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

[object Object]
Preview
4.0
10-27Benzinga
Booking Holdings Expected to Surge by 12%? Check Out 10 Leading Analyst Predictions for Monday

  • Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including DraftKings, Avidity Biosciences, and Glaukos Corp, reflecting a mix of upgrades and downgrades.

  • Notable Price Target Increases: Avidity Biosciences saw its price target raised significantly by Bernstein, while Exagen and Estee Lauder also received upward adjustments from Canaccord Genuity.

  • Upgrades and Downgrades: Glaukos Corp was upgraded by Wells Fargo, while Kura Sushi USA experienced a downgrade from Benchmark, despite both maintaining Buy ratings.

  • Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.

[object Object]
Preview
4.0
10-23Yahoo Finance
Changing Perspectives on Exagen Amid Analyst Upgrades and Growth Indicators

  • Analyst Price Target Increase: Exagen's consensus analyst price target has risen from $11.17 to $13.14, indicating a more optimistic valuation due to improved business performance and the potential of its AVISE CTD diagnostic platform.

  • Bullish Analyst Sentiment: Analysts from B. Riley, Cantor Fitzgerald, and KeyBanc have expressed positive outlooks, with B. Riley initiating coverage with a Buy rating and a $15 target, while Cantor Fitzgerald and KeyBanc also raised their price targets, highlighting strong operational results and revenue guidance.

  • S&P Global BMI Index Inclusion: Exagen has been added to the S&P Global BMI Index, which may enhance its visibility and credibility in the investment community, alongside projecting a revenue range of $65 million to $70 million for fiscal year 2025.

  • Future Financial Expectations: The company anticipates achieving positive adjusted EBITDA by Q4 2025 if it meets its revenue targets, with slight adjustments in discount rates and net profit margin outlooks reflecting a higher projected earnings valuation.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Exagen Inc (XGN) stock price today?

The current price of XGN is 7.49 USD — it has increased 2.88 % in the last trading day.

arrow icon

What is Exagen Inc (XGN)'s business?

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

arrow icon

What is the price predicton of XGN Stock?

Wall Street analysts forecast XGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XGN is 16.20 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Exagen Inc (XGN)'s revenue for the last quarter?

Exagen Inc revenue for the last quarter amounts to 17.24M USD, increased 37.87 % YoY.

arrow icon

What is Exagen Inc (XGN)'s earnings per share (EPS) for the last quarter?

Exagen Inc. EPS for the last quarter amounts to -0.31 USD, increased 10.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Exagen Inc (XGN)'s fundamentals?

The market is revising Downward the revenue expectations for Exagen Inc. (XGN) for FY2025, with the revenue forecasts being adjusted by -0.09% over the past three months. During the same period, the stock price has changed by -22.54%.
arrow icon

How many employees does Exagen Inc (XGN). have?

Exagen Inc (XGN) has 203 emplpoyees as of December 05 2025.

arrow icon

What is Exagen Inc (XGN) market cap?

Today XGN has the market capitalization of 169.75M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free